Sacituzumab govitecan (solution)
Based on 12 publication(s) in Google Scholar
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.19%
- CAS No.: 1491917-83-9
- 분자량:157364 (average)
-
보관:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
-
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P99045
SacituzumabAnti-TROP-2 Antibody -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC -
HY-P99016B
Enfortumab vedotin-ejfv (solution)Nectin-4 ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-13704
SN-38Topoisomerase I Inhibitor -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921A
Trastuzumab emtansine (solution)Antibody-Drug Conjugate -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate
Publications Citing Use of MedChemExpress (MCE) Sacituzumab govitecan (solution)
More- Nature. 2026 Aug;656(8129):1023-1033.
- Cell Rep Med. 2026 Apr 21;7(4):102688. [Abstract]
- J Control Release. 2024 Mar:367:779-790. [Abstract]
- Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
- Int J Biol Macromol. 2025 Apr 3;309(Pt 1):142843. [Abstract]
- Anal Chem. 2025 Oct 28;97(42):23598-23608. [Abstract]
- J Med Chem. 2025 Jul 20. [Abstract]
- Oncol Res. 2025 Nov 27;33(12):3973-3989. [Abstract]
- Gynecol Oncol. 2025 May 8:197:129-138. [Abstract]
- Bioorg Med Chem. 2024 Aug 1:110:117828. [Abstract]
- medRxiv. 2026 Apr 18.
- Patent. US20240293379A1.
Customer Validation & Images
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
Biological Activity
제품 설명
In Vitro
Sacituzumab govitecan (10 µM; 48 h) upregulates the early pro-apoptotic signaling markers (cleaved caspase3/7, cleaved PARP, p53 and p21), causes PARP cleavage and apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:NCI-N87, BxPC-3
-
Concentration:10 µM
-
Incubation Time:48 h
-
Result:Increased cleaved caspase 3/7 and cleaved PARP.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:mouse xenograft model[1]
-
Dosage:17.5 mg/kg
-
Administration:twice weekly for 4 weeks
-
Result:Inhibited tumor growth.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1491917-83-9
-
Appearance Liquid
-
분자량 157364 (average)
-
Color Colorless to light yellow
-
SMILES
[Sacituzumab govitecan (solution)]
-
Synonyms
IMMU-132 (solution)
-
선적
Shipping with dry ice.
-
보관
-80°C, protect from light
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
-
Cell Rep Med
A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. [Abstract]2026 Apr 21;7(4):102688. PMID: 41856115 -
J Control Release
In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. [Abstract]2024 Mar:367:779-790. PMID: 38346501 -
Cell Death Dis
MMP1-induced NF-κB activation promotes epithelial-mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer. [Abstract]2025 Apr 26;16(1):346. PMID: 40287412
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
Cell morphology was observed under a microscope (SG, 10 nM, 24 h) (Scale bar: 100 µm).
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
Cell viability was assessed after 24 h of treatment with 10 nM SG at various concentrations using the CCK-8 assay.
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
Representative fluorescence images and quantification of tail moment in parental and resistant cells (SG, 10 nM, 24 h).
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
The heatmap displays gene expression in the resistant group compared to the parental group in MCF-7 cells (SG, 10 nM, 24 h). The colors of the heatmap reflect log2 expression levels of genes.
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Apr 26;16(1):346. [Abstract]
After knockdown of BCL2A1, WFDC3, PI3, CLDN5, and MMP1 separately, the viability of MCF-7-Pa and T47D-Pa was tested at different concentrations of SG (0-200 nM) using CCK-8 assays.
-
Int J Biol Macromol
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy. [Abstract]2025 Apr 3;309(Pt 1):142843. PMID: 40187454 -
Anal Chem
Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer. [Abstract]2025 Oct 28;97(42):23598-23608. PMID: 41105928
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Anal Chem. 2025 Oct 28;97(42):23598-23608. [Abstract]
Time course of tumor volume of MDA-MB-468 tumor-bearing mice treated with PBS, SG (10 mg/kg, tail vein injection), and Dato-DXd (10 mg/kg, tail vein injection).
Sacituzumab govitecan (solution) purchased from MedChemExpress. Usage Cited in: Anal Chem. 2025 Oct 28;97(42):23598-23608. [Abstract]
MicroPET imaging of MDA-MB-468 tumor-bearing mice at different time postinjection of [68Ga]Ga-NOTA-PEG2-WP8 during PBS, SG (10 mg/kg, tail vein injection) and Dato-DXd (10 mg/kg, tail vein injection) treatment for 0, 9, and 18 days, respectively. White dotted line circles indicate the tumor locations.
-
J Med Chem
2025 Jul 20. PMID: 40685636 -
Oncol Res
TROP-2 Promotes Cell Proliferation via the AKT-Mediated PKC α Pathway and Is a Novel Target for Antibody-Drug Conjugates in Penile Carcinoma. [Abstract]2025 Nov 27;33(12):3973-3989. PMID: 41425706 -
Gynecol Oncol
2025 May 8:197:129-138. PMID: 40344963 -
Bioorg Med Chem
2024 Aug 1:110:117828. PMID: 38981219 -
-
순도&문서
-
Data Sheet (274 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]
[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512. [Content Brief]
[3]. Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sacituzumab govitecan (solution) Related Classifications
HY-132254A Related Classifications
Powered by Bioz